Searched for
OBESITY MARKET FORECAST
Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cutsPfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The co...- US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipelineIndian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...
- Novo Nordisk launches once-weekly basal insulin 'Awiqli' in India as diabetes rates increaseNovo Nordisk has launched Awiqli, a new weekly basal insulin injection, in India. This innovative drug offers a once-weekly alternative to ...
- Pfizer CFO Dave Denton to leave company in AugustPfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure r...
- US stocks today: S&P 500 and Nasdaq hit record closing highs as US and Iran agree to extend ceasefireThe S&P 500 and Nasdaq hit record closing highs as hopes of a US Iran ceasefire extension boosted sentiment. Investors also digested US inf...
- Novo Nordisk uses AI to fast-track drug launches, expand India roleNovo Nordisk is leveraging Artificial Intelligence to significantly speed up new drug launches. The company expects to cut down the time to...
- US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- LLY stock jumps 9%: Why Eli Lilly stock is soaring today - Mounjaro, Zepbound sales drive massive earnings beat and 2026 forecast stuns Wall StreetLLY stock today: Eli Lilly's stock saw a significant jump following impressive fourth-quarter results and a strong 2026 financial forecast....
- Tech stocks pull European shares lower; earnings in focusEuropean shares dipped to a two-week low on Wednesday, mirroring global investor nervousness over elevated equity valuations. Technology st...
- Pfizer, Novo Nordisk escalate bidding war for obesity drug developer MetseraA fierce bidding war is underway for Metsera, an obesity drug developer. Novo Nordisk has made a $10 billion offer, which Metsera considers...
- Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera: ReportPfizer is close to acquiring Metsera, an anti-obesity drug developer. The deal could be worth $7.3 billion. Pfizer will pay $47.50 per shar...
- Eli Lilly Q2 earnings beat expectations on Mounjaro, Zepbound sales, stock falls after obesity drug trial missLilly stock latest news: Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year gu...
- Obesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlookNovo Nordisk has reduced its sales and profit growth predictions for 2025. The company cites lower expectations for Wegovy in the U.S. obes...
- Govt to release nutrient guidelines for all age groups soonThe government in India will soon release nutrient guidelines. These guidelines will cover all age groups. They will specify minimum requir...
- Novo Nordisk India execs urge early Wegovy launch as weight-loss rival loomsNovo Nordisk's team in India is urging the company to launch its popular weight-loss drug, Wegovy, next year to stay ahead of rival Eli Lil...
- Ozempic frenzy lures rich Indians to brave the gray marketPeople are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying coun...
- Eli Lilly rises 6%; company raises 2024 sales forecast by $2 billionExplosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales...
- Weight-loss drugs: Who, and what, are they good for?The new drugs are known as GLP-1 agonists, which mimic the activity of a hormone that slows digestion and helps people feel full for longer...
- Biggest pharma blockbuster? All about Wegovy, Novo Nordisk's obesity drug, that cuts risk of heart attacks and strokes by 20%In a groundbreaking achievement, Novo Nordisk's obesity medication Wegovy has not only demonstrated its efficacy in substantial weight loss...
Load More
